A guide to enclomiphene citrate safety for men aged 18, 29, covering testosterone restoration, fertility preservation, adverse effects, monitoring protocols, and current guideline positions.
A clinician-level review of enclomiphene citrate's cardiovascular effects in men with secondary hypogonadism, covering lipid profiles, blood pressure, erythrocytosis risk, and how it compares to exogenous testosterone therapy.
A physician-level review of enclomiphene citrate for secondary hypogonadism in post-bariatric men: pharmacokinetics, absorption concerns, dosing adjustments, monitoring targets, and the evidence base including Kim et al. 2016.
A deep dive into what happens to testosterone, LH, FSH, and spermatogenesis after stopping enclomiphene citrate, including timeline data, risk factors, and clinical restart protocols.
A guide to how enclomiphene citrate affects libido, erectile function, and sperm production in men with secondary hypogonadism, with primary-literature citations and dosing context.
A clinical review of how epitalon tetrapeptide may affect appetite, food cravings, and metabolic signaling. Covers mechanism, trial data, dosing context, and what patients report.
A deep dive into how the tetrapeptide epitalon may affect cognitive function, covering telomerase biology, circadian signaling, animal and human trial data, and current clinical guidance.
A GRADE-level analysis of every published human and animal study on epitalon tetrapeptide, covering telomerase activation, circadian regulation, cancer endpoints, and longevity cohort data. Reviewed by board-certified physicians.
A clinical review of epitalon tetrapeptide and its effects on kidney function, including renal protection mechanisms, potential risks, and what current evidence means for patients and prescribers.
A guide to how transdermal estradiol affects hair growth, hair loss, skin thickness, collagen, and wound healing, with primary-literature citations and clinical dosing guidance.
A clinical review of alprostadil pharmacogenomics, dosing adjustments, and safety considerations specific to East Asian patients, including CYP enzyme variation, BMI thresholds, and ethnicity-stratified trial data.
A guide to AndroGel pharmacogenomics, dosing thresholds, and safety considerations specific to East Asian patients, with cited trial data and pharmacogenomic references.
A clinical review of BPC-157 dosing for Hispanic and Latino patients, covering pharmacogenomics, diabetes-related considerations, CYP variant data, and practical prescribing guidance prepared by the HealthRX.com Editorial Team.
A detailed clinical review of enclomiphene citrate safety, pharmacogenomics, and dosing considerations specific to Black and African ancestry patients, including G6PD prevalence, cardiovascular risk, CKD overlap, and ethnicity-stratified evidence.
A clinical review of GHK-Cu (copper tripeptide) efficacy differences in East Asian patients, covering pharmacogenomics, ethnicity-stratified data, dosing considerations, and what providers need to know before prescribing.
A clinical deep-dive into how GHK-Cu (copper tripeptide) may behave differently in South Asian patients, covering pharmacogenomics, copper metabolism, dosing considerations, and ethnicity-specific safety signals.
A deep dive into how East Asian pharmacogenomics, NNMT activity, CYP2C19/CYP2D6 variants, and lower BMI thresholds, shape NMN and NR efficacy, with ethnicity-stratified trial data and dosing guidance.
A guide to oral minoxidil dosing for South Asian patients, covering cardiovascular risk, pharmacogenomics, ethnicity-stratified data, and practical starting doses.
A clinician-focused review of semaglutide 0.5 to 2.0 mg efficacy differences in Hispanic and Latino patients, covering ethnicity-stratified RCT subgroup data, pharmacogenomics, insulin resistance phenotypes, and dosing considerations.
A clinician-grade review of sermorelin acetate pharmacogenomics, pharmacokinetics, and dose-adjustment considerations specific to patients of Black or African ancestry, with cited trial data and practical guidance.
A clinical review of sermorelin acetate pharmacogenomics, GH-axis physiology, and race-stratified evidence relevant to Black and African ancestry patients, including dosing considerations and documented efficacy gaps.
A clinical deep-dive into spironolactone pharmacogenomics, ethnicity-stratified trial data, and dosing considerations for Hispanic and Latino patients with acne.
A guide to tadalafil pharmacogenomics, dosing, and safety considerations specific to patients of Black or African ancestry, with ethnicity-stratified data, guideline citations, and practical prescribing guidance.
A clinical deep-dive into tesamorelin efficacy, pharmacogenomics, and dosing considerations specific to Black and African ancestry patients, with inline citations to primary sources.
A clinical evidence review of how East Asian pharmacogenomics, body-composition norms, and androgen-receptor biology may affect testosterone cypionate dosing, monitoring, and safety discussions, with an explicit map of what is established versus extrapolated.
A guide to how tretinoin (topical retinoic acid) behaves differently in South Asian skin: pharmacogenomics, pigmentation risk, dosing adjustments, and monitoring protocols backed by primary sources.
Evidence-based guidance on vardenafil dosing for South Asian men, covering CYP3A4/CYP3A5 pharmacogenomics, elevated CV risk at lower BMI, drug interactions with metformin and statins, and practical starting-dose recommendations.
A clinician-focused review of semaglutide 2.4 mg dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, ethnicity-stratified trial data, and practical titration guidance.
A deep dive into how finasteride works, its 5-alpha-reductase inhibition mechanism, oral dosing, and why injectable forms are not used in standard practice. Includes trial data, dosing tables, and clinical FAQs.
Find out whether TRICARE covers finasteride for hair loss or BPH, what prior authorization looks like, which formulary tier it sits on, and how to appeal a denial step by step.
A guide to finasteride dosing for men aged 18, 29, covering 1 mg AGA and 5 mg BPH protocols, fertility considerations, sexual side-effect data, and monitoring recommendations.
A clinician-level review of finasteride's interactions with autoimmune conditions, including immune-mediated hair loss, post-finasteride syndrome debate, and prescribing considerations for patients with lupus, psoriasis, or other autoimmune diagnoses.
A clinician-level review of how finasteride is absorbed, metabolized, and excreted, plus an evidence-based look at its effects on energy expenditure, thermogenesis, and body composition.
A deep dive into finasteride microdosing for androgenetic alopecia, covering dose-response pharmacology, DHT suppression at sub-milligram doses, side-effect considerations, and what a clinician conversation about off-label dosing should cover.
A clinical deep-dive into how finasteride affects muscle mass, strength, and recovery, and the specific strategies men on finasteride can use to protect their gains, prepared by the HealthRX.com Editorial Team.
Evidence-based guidance on when and how to restart finasteride (1 mg or 5 mg) after acute illness, fever, surgery, or hospitalization. Covers hair loss regression, DHT rebound timing, dose re-titration, and red-flag conditions that require pausing therapy.
A detailed look at Medicare Advantage coverage policies for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary status, appeal rights, and cash-pay alternatives for premenopausal women with HSDD.
A deep dive into flibanserin (Addyi) cardiovascular safety data, including hypotension, syncope, drug interactions, and long-term heart risk. Includes BEGONIA trial data, FDA REMS requirements, and clinical management guidance.
A clinician-level review of flibanserin (Addyi) and kidney safety: pharmacokinetics, renal dosing, drug interactions, and what current evidence says about renal protection versus renal risk.
A guide to copper tripeptide GHK-Cu for post-surgical recovery, covering the current evidence base, dosing protocols, side effects, and how it compares to other tissue-repair peptides.
A guide to copper tripeptide GHK-Cu dosing in adults 65 and older, covering renal considerations, falls risk, drug interactions, and compounding pharmacy protocols.
A guide to GHK-Cu (copper tripeptide) safety in children under 12, covering FDA status, copper toxicity thresholds, dosing considerations, and why no pediatric trials exist for this compound.
An evidence-based analysis of GHK-Cu (copper tripeptide) and the kidneys, covering preclinical renal-protection data, copper nephrotoxicity thresholds, and clinical guidance for patients using compounded GHK-Cu peptides.
A clinician-level review of copper tripeptide GHK-Cu and its documented effects on sleep architecture, including mechanisms, trial data, dosing context, and what remains unknown.
Evidence-based guidance for travelers using GHK-Cu, including the lack of a validated dosing protocol, product-specific storage questions, FDA compounding concerns, and CDC jet-lag strategies.
A clinical breakdown of 503A vs 503B pharmacy classifications, compounded GLP-1 legal status after the shortage resolutions, how to verify a legitimate pharmacy, and how compounded semaglutide and tirzepatide compare to brand-name Wegovy and Zepbound in safety and dosing.
A guide to GLP-1 receptor agonists in adolescents and across hormonal life stages, covering FDA approvals, trial data, dosing, and metabolic conditions including PCOS, T2D, prediabetes, and perimenopause.
A cross-trial comparison of PIONEER-1, PIONEER-4, PIONEER-6, and OASIS-1 examining oral semaglutide's A1C reduction, weight loss at 50 mg, cardiovascular non-inferiority, and gastrointestinal tolerability versus injectable GLP-1 agents.
A rigorous side-by-side comparison of STEP-1 (semaglutide 2.4 mg) and SURMOUNT-1 (tirzepatide 5/10/15 mg) for chronic weight management, covering matched outcomes, population differences, methodology gaps, and what the two trials together do and do not establish.
Tirzepatide cut weight by roughly 21% in obesity, 16% with type 2 diabetes, and up to 26% with a lifestyle lead-in across the four SURMOUNT trials.
A detailed guide to compounded semaglutide and tirzepatide legal status in 2025, covering the FDA shortage list, 503A vs 503B pharmacy rules, how to verify a compounding pharmacy, and safety differences between compounded and brand-name GLP-1 medications.
Real 2025 prices for Wegovy, Zepbound, Ozempic, Mounjaro, and compounded semaglutide. Covers list price, insurance, manufacturer savings cards, and compounded alternatives with clinical context.
Exact out-of-pocket costs for Zepbound, Wegovy, Ozempic, and Mounjaro in 2025, plus compounded GLP-1 pricing, insurance rules, and savings programs explained with clinical context.
The reflexive position that all compounded semaglutide and tirzepatide is unsafe ignores the 503A statutory framework and the real access gap. The HealthRX.com Medical Team argues that properly-licensed 503A compounding with physician oversight is a defensible option, and explains exactly what 'properly-licensed' requires.
Sub-FDA-approved doses of semaglutide and tirzepatide are spreading through telehealth without RCT support. The HealthRX.com Medical Team argues that dose-finding rationale does not equal efficacy data, and that patients deserve that distinction made explicit.
Weight regain after semaglutide discontinuation is not a side-effect or a failure, it is the pharmacology. The HealthRX.com Medical Team argues the STEP-1 extension data obligates us to reframe GLP-1 agonists as chronic-disease therapy from the first prescription.
Evidence-based guide to maintaining weight loss long-term on GLP-1 receptor agonists, including what happens when you stop semaglutide or tirzepatide, how to taper, what the clinical trials say about weight regain, and how to switch between agents.
Mounjaro (tirzepatide) led to 20.9% average weight loss at 72 weeks in trials, outperforming semaglutide. See dosing, FDA status, and how it compares.
Ozempic face is the gaunt, sagging appearance that can follow rapid GLP-1-driven weight loss. Learn the physiology behind facial volume loss, the protein and resistance-training targets that limit it, and when filler or skin-tightening procedures are appropriate.
A clinical deep-dive into why GLP-1 receptor agonist weight loss slows or stops, with evidence-based strategies for titration adjustment, missed-dose management, microdosing, and long-term maintenance dosing.